In summary, we determined prospective therapeutics targeting the role of MEIS1 in oxaliplatin resistance, and that ELFN1-AS1 or EZH2 can be potential targets for treating oxaliplatin-resistant CRC by promoting MEIS1 expression. The gene discussed is EZH2; the disease is colorectal carcinoma.